U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Suh	stitute	for form 1	449/PTO			Complete if known			
~ ~ ~		•				Application Number	10/559,814		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT						Filing Date	April 4, 2006		
						First Named Inventor Mark B. Pepys			
(Use as many sheets as necessary)						Art Unit	1646	16	
(Use as many sneets as necessar				. 45	Examiner Name		Net-Vet-Assigned Ruixian		
Sheet		1	of			Attorney Docket Number	068800-0324485		
					U.S. PATENT	DOCUMENTS			
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)			Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, where Relevant Passages or Relevant		
	INO.				MIN-DD-1111	Applicant of Citoa Docui	Figures Appear	Figures Appear	
	AA	US-							
	AB	US-							
	AC	US-							
	AD	US-							
	AE	US-							
	AF	US-		*					
	AG	US-							
	AH	US-							
	-			1	FOREIGN PATEN	T DOCUMENTS			
Examiner Initials*	Cite	Foreign Patent Document			Publication Date	Name of Patentee or	Pages, Columns, Lines, where Relevant Passages or Relevant	T ⁶	
	No.1		Country Code ³ -Number ⁴ - MM-DD-YYY Kind Code ⁵ (if known)		MM-DD-YYYY	Applicant of Cited Docum	nt Figures Appear	_	
	ΑĬ								
	АJ								
	AK								
	AL								
	AM								
				NON	PATENT LITERA	TURE DOCUMENTS			
Examiner Initials*	Cite No.	(book, m	agazine, jo		l, symposium, catal	RS), title of the article (when og, etc.), date, page(s), volum	appropriate), title of the item ne-issue number(s), publisher, city	T6	
	AN					amine and a Thiazole Derivat	ive, SM-8849, on Pristane-		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	AN	Nishukaku et. al., "Protective Effects of D-Penicillamine and a Thiazole Derivative, SM-8849, on Pristane-Induced Arthritis in Mice," International Journal of Immunopharmacology, vol. 16, no 2 pp 91-100, 1994.	
	AO	Danielsen et. al., "Calcium-dependent and -independent binding of the pentraxin serum amyloid P component to glycosaminoglycans and amyloid proteins: enhanced binding at slightly acid pH," Biochimica et Biophysica Acta 1339 (1997) 73-78	
	AP		
	AQ		
	AR		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date Considered

/Ruixiang Li/

Examiner Signature

09/22/2009